THERANEXUS EO -,25 WKN: A2H6LX ISIN: FR0013286259 Forum: Aktien Thema: Hauptdiskussion

Hallo 🖐🖐 Cash: Total available funds as of September 30, 2019 stood at €9,542,000 compared to €10,231,000 as of June 30, 2019, reflecting effective cost control. This excludes the French Research Tax Credit for 2018 (€1.7m), which was collected at the beginning of October. THN102: This trial conducted in Europe and the United States evaluates the tolerance and efficacy of THN102 on non-motor symptoms in Parkinson's disease patients. Trial results expected in Q1 2020 THN201: This study compares the efficacy of THN201 with the standard-of-care drug in Alzheimer's disease associated neurocognitive disorders Results are expected towards the end of 2019 https://www.theranexus.com/en/